India, Aug. 18 -- GenScript Biotech Corp. (1548.HK) on Tuesday reported stronger adjusted net profit for the first half of fiscal 2026 compared to the same period last year.
For the six months ended June 30, adjusted net profit surged more than three-fold to $62.5 million, up from $20.6 million last year.
Revenue rose to $404.2 million from $317.4 million a year earlier.
GenScript said it enters the second half of 2026 with continued momentum across its Life Science Group, ProBio and Bestzyme units, supported by a growing order base across core businesses. The company expects higher demand, increased utilization across its global network and further operating leverage to drive revenue growth and profitability.
googletag.cmd.push(functio...